Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Harvard Business School
Queensland Health
Daiichi Sankyo

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,125,846

« Back to Dashboard

Which drugs does patent 6,125,846 protect, and when does it expire?

Patent 6,125,846 protects INOMAX and is included in one NDA. There has been one Paragraph IV challenge on INOmax.

Protection for INOMAX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 6,125,846

Title: Purge system for nitric oxide administration apparatus
Abstract:A nitric oxide delivery system is disclosed that delivers a pulsed volume of NO containing therapeutic gas to a patient upon each inhalation of the patient. The NO delivery system includes certain functions to provide protection against the inadvertent inclusion of NO.sub.2 in the therapeutic gas administered to the patient. One of the functions is to provide a purge upon start up of the delivery system apparatus that clears the regulator and conduits of any NO.sub.2 that may have formed during the prior idle period of the system. A detector determines the start-up and may automatically carry out the purge cycle or may cause a prompt that is visual or audible to remind the user to carry out the purge cycle manually. As a further function, when the NO apparatus is terminated with respect to a patient, the system can, again, sense the termination or cessation of the therapy and automatically shut off the supply of NO containing gas at the source or provide an audible or visual prompt to remind the user to shut off the supply of the NO containing gas manually.
Inventor(s): Bathe; Duncan P. L. (Madison, WI), Montgomery; Frederick J. (Sun Prairie, WI)
Assignee: Datex-Ohmeda, Inc. (Madison, WI)
Application Number:08/857,925
Patent Claim Types:
see list of patent claims
Use; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Mallinckrodt Hosp
nitric oxide
GAS;INHALATION020845-002Dec 23, 1999DISCNYesNo► Subscribe► SubscribeY
Mallinckrodt Hosp
nitric oxide
GAS;INHALATION020845-003Dec 23, 1999RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
US Army
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus